首页 > 最新文献

Transplantation Direct最新文献

英文 中文
Clinical Course, Immunogenicity, and Efficacy of BNT162b2 mRNA Vaccination Against SARS-CoV-2 Infection in Liver Transplant Recipients. 肝移植受者接种BNT162b2信使核糖核酸疫苗对抗严重急性呼吸系统综合征冠状病毒2型感染的临床过程、免疫原性和疗效。
IF 2.3 Q3 TRANSPLANTATION Pub Date : 2023-09-20 eCollection Date: 2023-10-01 DOI: 10.1097/TXD.0000000000001537
Eunice X Tan, Wen Hui Lim, Elizabeth Thong, Jean-Marc Chavatte, Jinyan Zhang, Jonathan Lim, Jocelyn Y Jin, Daniel R X Lim, Jaclyn Y T Kang, Ansel Shao Pin Tang, Kai En Chan, Caitlyn Tan, Shi Ni Tan, Benjamin Nah, Daniel Q Huang, Lin-Fa Wang, Paul A Tambyah, Jyoti Somani, Barnaby Young, Mark D Muthiah

Background: Immunocompromised individuals have been excluded from landmark studies of messenger RNA vaccinations for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). In such patients, the response to vaccination may be blunted and may wane more quickly compared with immunocompetent patients. We studied the factors associated with decreased antibody response to SARS-CoV-2 vaccination and risk factors for subsequent breakthrough infections in liver transplant (LT) patients undergoing coronavirus disease 2019 vaccination with at least 2 doses of messenger RNA vaccine from April 28, 2021, to April 28, 2022.

Methods: All LT recipients received at least 2 doses of the BNT162b2 (Pfizer BioNTech) vaccine 21 d apart. We measured the antibody response against the SARS-CoV-2 spike protein using the Roche Elecsys immunoassay to the receptor-binding domain of the SARS-CoV-2 spike protein, and the presence of neutralizing antibodies was measured by the surrogate virus neutralization test (cPass) before first and second doses of vaccination and also between 2 and 3 mo after the second dose of vaccination.

Results: Ninety-three LT recipients who received 2 doses of BNT162b2 were included in the analysis. The mean time from LT was 110 ± 154 mo. After 2-dose vaccination, 38.7% of LT recipients (36/93) were vaccine nonresponders on the cPass assay compared with 20.4% (19/93) on the Roche S assay. On multivariable analysis, increased age and increased tacrolimus trough were found to be associated with poor neutralizing antibody response (P = 0.038 and 0.022, respectively). The use of antimetabolite therapy in conjunction with tacrolimus approached statistical significance (odds ratio 0.21; 95% confidence interval, 0.180-3.72; P = 0.062). Breakthrough infection occurred in 18 of 88 LT recipients (20.4%). Female gender was independently associated with breakthrough infections (P < 0.001).

Conclusions: Among LT recipients, older age and higher tacrolimus trough levels were associated with poorer immune response to 2-dose SARS-CoV-2 vaccination. Further studies are needed to assess variables associated with breakthrough infections and, hence, who should be prioritized for booster vaccination.

背景:免疫受损的个体已被排除在信使核糖核酸疫苗接种严重急性呼吸综合征冠状病毒2型(严重急性呼吸系统综合征冠状病毒-2型)的里程碑式研究之外。在这类患者中,与具有免疫活性的患者相比,对疫苗接种的反应可能会减弱,并可能更快地减弱。我们研究了与严重急性呼吸系统综合征冠状病毒2型疫苗抗体反应降低相关的因素,以及在2021年4月28日至4月28日间接受2019冠状病毒病疫苗接种的肝移植(LT)患者随后突破性感染的风险因素,方法:所有LT受试者间隔21天至少接种2剂BNT162b2(辉瑞-BioNTech)疫苗。我们使用Roche Elecsys免疫测定法测量了针对严重急性呼吸系统综合征冠状病毒2型刺突蛋白的抗体反应,并在第一剂和第二剂疫苗接种前以及第二剂接种后2至3个月通过替代病毒中和试验(cPass)测量了中和抗体的存在。结果:93名接受2剂BNT162b2的LT受试者被纳入分析。LT的平均时间为110 ± 154个月。接种两剂疫苗后,38.7%的LT受试者(36/93)对cPass试验无反应,而罗氏S试验为20.4%(19/93)。多变量分析发现,年龄增加和他克莫司谷值增加与中和抗体反应差有关(P = 分别为0.038和0.022)。抗代谢治疗与他克莫司联合使用具有统计学意义(比值比0.21;95%置信区间,0.180-3.72;P = 突破性感染发生率为20.4%,女性与突破性感染独立相关(P 结论:在LT受试者中,年龄较大和他克莫司谷水平较高与对2剂严重急性呼吸系统综合征冠状病毒2型疫苗的免疫反应较差有关。需要进一步的研究来评估与突破性感染相关的变量,因此,谁应该优先接种加强针。
{"title":"Clinical Course, Immunogenicity, and Efficacy of BNT162b2 mRNA Vaccination Against SARS-CoV-2 Infection in Liver Transplant Recipients.","authors":"Eunice X Tan,&nbsp;Wen Hui Lim,&nbsp;Elizabeth Thong,&nbsp;Jean-Marc Chavatte,&nbsp;Jinyan Zhang,&nbsp;Jonathan Lim,&nbsp;Jocelyn Y Jin,&nbsp;Daniel R X Lim,&nbsp;Jaclyn Y T Kang,&nbsp;Ansel Shao Pin Tang,&nbsp;Kai En Chan,&nbsp;Caitlyn Tan,&nbsp;Shi Ni Tan,&nbsp;Benjamin Nah,&nbsp;Daniel Q Huang,&nbsp;Lin-Fa Wang,&nbsp;Paul A Tambyah,&nbsp;Jyoti Somani,&nbsp;Barnaby Young,&nbsp;Mark D Muthiah","doi":"10.1097/TXD.0000000000001537","DOIUrl":"10.1097/TXD.0000000000001537","url":null,"abstract":"<p><strong>Background: </strong>Immunocompromised individuals have been excluded from landmark studies of messenger RNA vaccinations for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). In such patients, the response to vaccination may be blunted and may wane more quickly compared with immunocompetent patients. We studied the factors associated with decreased antibody response to SARS-CoV-2 vaccination and risk factors for subsequent breakthrough infections in liver transplant (LT) patients undergoing coronavirus disease 2019 vaccination with at least 2 doses of messenger RNA vaccine from April 28, 2021, to April 28, 2022.</p><p><strong>Methods: </strong>All LT recipients received at least 2 doses of the BNT162b2 (Pfizer BioNTech) vaccine 21 d apart. We measured the antibody response against the SARS-CoV-2 spike protein using the Roche Elecsys immunoassay to the receptor-binding domain of the SARS-CoV-2 spike protein, and the presence of neutralizing antibodies was measured by the surrogate virus neutralization test (cPass) before first and second doses of vaccination and also between 2 and 3 mo after the second dose of vaccination.</p><p><strong>Results: </strong>Ninety-three LT recipients who received 2 doses of BNT162b2 were included in the analysis. The mean time from LT was 110 ± 154 mo. After 2-dose vaccination, 38.7% of LT recipients (36/93) were vaccine nonresponders on the cPass assay compared with 20.4% (19/93) on the Roche S assay. On multivariable analysis, increased age and increased tacrolimus trough were found to be associated with poor neutralizing antibody response (<i>P</i> = 0.038 and 0.022, respectively). The use of antimetabolite therapy in conjunction with tacrolimus approached statistical significance (odds ratio 0.21; 95% confidence interval, 0.180-3.72; <i>P</i> = 0.062). Breakthrough infection occurred in 18 of 88 LT recipients (20.4%). Female gender was independently associated with breakthrough infections (<i>P</i> < 0.001).</p><p><strong>Conclusions: </strong>Among LT recipients, older age and higher tacrolimus trough levels were associated with poorer immune response to 2-dose SARS-CoV-2 vaccination. Further studies are needed to assess variables associated with breakthrough infections and, hence, who should be prioritized for booster vaccination.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"9 10","pages":"e1537"},"PeriodicalIF":2.3,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/12/bd/txd-9-e1537.PMC10513132.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41152359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reproducibility of Rejection Grading in Uterus Transplantation: A Multicenter Study. 子宫移植排斥反应分级的可重复性:一项多中心研究。
IF 2.3 Q3 TRANSPLANTATION Pub Date : 2023-09-20 eCollection Date: 2023-10-01 DOI: 10.1097/TXD.0000000000001535
Verena Broecker, Mats Brännström, Hans Bösmüller, Eva Sticová, Jana Malušková, Andres Chiesa-Vottero, Johan Mölne

Background: Diagnosis of rejection after uterus transplantation is based on histopathological examination of ectocervical biopsies. Inflammation at the stromal-epithelial interface is the backbone of the histopathological classification proposed by our group in 2017. However, the reproducibility of this grading scheme has not been tested, and it is unclear whether it covers the full morphological spectrum of rejection.

Methods: We present a multicenter study in which 5 pathologists from 4 uterus transplantation centers performed 2 rounds of grading on 145 and 48 cervical biopsies, respectively. Three of the centers provided biopsies. Additionally, the presence of perivascular stromal inflammation was recorded. During discussions after the first round, further histological lesions (venous endothelial inflammation and apoptosis) were identified for closer evaluation and added to the panel of lesions to score in the second round. All participants completed a questionnaire to explore current practices in handling and reporting uterus transplant biopsies.

Results: Cervical biopsies were commonly performed in all centers to monitor rejection. Intraobserver reproducibility of rejection grading (performed by 1 rater) was excellent, whereas interobserver reproducibility was moderate and did not improve in the second round. Reproducibility of perivascular stromal inflammation was moderate but unsatisfactory for venous endothelial inflammation and apoptosis. All lesions were more frequent in, but not restricted to, biopsies with rejection patterns.

Conclusions: Grading of rejection in cervical biopsies is reproducible and applicable to biopsies from different centers. Diagnosis of rejection may be improved by adding further histological lesions to the grading system; however, lesions require rigorous consensus definition.

背景:子宫移植后排斥反应的诊断是基于子宫颈外活检的组织病理学检查。基质-上皮界面的炎症是我们小组2017年提出的组织病理学分类的支柱。然而,该分级方案的再现性尚未得到测试,也不清楚它是否涵盖了排斥反应的全部形态谱。方法:我们进行了一项多中心研究,来自4个子宫移植中心的5名病理学家分别对145例和48例宫颈活检进行了两轮分级。其中三个中心提供了活组织检查。此外,还记录了血管周围基质炎症的存在。在第一轮讨论后的讨论中,进一步的组织学损伤(静脉内皮炎症和细胞凋亡)被确定为更仔细的评估,并被添加到损伤小组中,在第二轮中进行评分。所有参与者都完成了一份问卷调查,以探讨目前处理和报告子宫移植活组织检查的做法。结果:所有中心都普遍进行宫颈活检以监测排斥反应。排斥反应分级(由1名评分者进行)的观察者内再现性良好,而观察者间再现性中等,在第二轮中没有改善。血管周围基质炎症的再现性中等,但静脉内皮炎症和细胞凋亡的再现性不令人满意。所有病变在具有排斥模式的活检中更为常见,但不限于此。结论:宫颈活检中排斥反应的分级是可重复的,适用于不同中心的活检。排斥反应的诊断可以通过在分级系统中添加更多的组织学损伤来改善;然而,病变需要严格的一致定义。
{"title":"Reproducibility of Rejection Grading in Uterus Transplantation: A Multicenter Study.","authors":"Verena Broecker,&nbsp;Mats Brännström,&nbsp;Hans Bösmüller,&nbsp;Eva Sticová,&nbsp;Jana Malušková,&nbsp;Andres Chiesa-Vottero,&nbsp;Johan Mölne","doi":"10.1097/TXD.0000000000001535","DOIUrl":"https://doi.org/10.1097/TXD.0000000000001535","url":null,"abstract":"<p><strong>Background: </strong>Diagnosis of rejection after uterus transplantation is based on histopathological examination of ectocervical biopsies. Inflammation at the stromal-epithelial interface is the backbone of the histopathological classification proposed by our group in 2017. However, the reproducibility of this grading scheme has not been tested, and it is unclear whether it covers the full morphological spectrum of rejection.</p><p><strong>Methods: </strong>We present a multicenter study in which 5 pathologists from 4 uterus transplantation centers performed 2 rounds of grading on 145 and 48 cervical biopsies, respectively. Three of the centers provided biopsies. Additionally, the presence of perivascular stromal inflammation was recorded. During discussions after the first round, further histological lesions (venous endothelial inflammation and apoptosis) were identified for closer evaluation and added to the panel of lesions to score in the second round. All participants completed a questionnaire to explore current practices in handling and reporting uterus transplant biopsies.</p><p><strong>Results: </strong>Cervical biopsies were commonly performed in all centers to monitor rejection. Intraobserver reproducibility of rejection grading (performed by 1 rater) was excellent, whereas interobserver reproducibility was moderate and did not improve in the second round. Reproducibility of perivascular stromal inflammation was moderate but unsatisfactory for venous endothelial inflammation and apoptosis. All lesions were more frequent in, but not restricted to, biopsies with rejection patterns.</p><p><strong>Conclusions: </strong>Grading of rejection in cervical biopsies is reproducible and applicable to biopsies from different centers. Diagnosis of rejection may be improved by adding further histological lesions to the grading system; however, lesions require rigorous consensus definition.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"9 10","pages":"e1535"},"PeriodicalIF":2.3,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/89/txd-9-e1535.PMC10513355.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41163704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cell-mediated and Neutralizing Antibody Responses to the SARS-CoV-2 Omicron BA.4/BA.5-adapted Bivalent Vaccine Booster in Kidney and Liver Transplant Recipients. 肾和肝移植受者对严重急性呼吸系统综合征冠状病毒2型奥密克戎BA.4/BA5-适应的二价疫苗加强剂的细胞介导和中和抗体反应。
IF 1.9 Q3 TRANSPLANTATION Pub Date : 2023-09-20 eCollection Date: 2023-10-01 DOI: 10.1097/TXD.0000000000001536
Mario Fernández-Ruiz, Patricia Almendro-Vázquez, Natalia Redondo, Tamara Ruiz-Merlo, Sandra Abella, Adán Somoza, Francisco López-Medrano, Rafael San Juan, Carmelo Loinaz, Amado Andrés, Estela Paz-Artal, José María Aguado

Background: The immunogenicity elicited by the Omicron BA.4/BA.5-adapted bivalent booster vaccine after solid organ transplantation (SOT) has not been characterized.

Methods: We assessed cell-mediated and neutralizing IgG antibody responses against the BA.4/BA.5 spike receptor-binding domain at baseline and 2 wk after the administration of an mRNA-based bivalent (ancestral strain and BA.4/BA.5 subvariants) vaccine among 30 SOT recipients who had received ≥3 monovalent vaccine doses. Previous coronavirus disease 2019 history was present in 46.7% of them. We also recruited a control group of 19 nontransplant healthy individuals. Cell-mediated immunity was measured by fluorescent ELISpot assay for interferon (IFN)-γ secretion, whereas the neutralizing IgG antibody response against the BA.4/BA.5 spike receptor-binding domain was quantified with a competitive ELISA.

Results: The median number of BA.4/BA.5 spike-specific IFN-γ-producing spot-forming units (SFUs) increased from baseline to 2 wk postbooster (83.8 versus 133.0 SFUs/106 peripheral blood mononuclear cells; P = 0.0017). Seropositivity rate also increased (46.7%-83.3%; P = 0.001), as well as serum neutralizing activity (4.2%-78.3%; P < 0.0001). Patients with no prior coronavirus disease 2019 history experienced higher improvements in cell-mediated and neutralizing responses after booster vaccination. There was no correlation between BA.4/BA.5 spike-specific IFN-γ-producing SFUs and neutralizing activity. Nontransplant controls showed more robust postbooster cell-mediated immunity than SOT recipients (591.1 versus 133.0 IFN-γ-producing SFUs/106 peripheral blood mononuclear cells; P < 0.0001), although no differences were observed for antibody responses in terms of postbooster seropositivity rates or neutralizing activity.

Conclusions: Booster with the BA.4/BA.5-adapted bivalent vaccine generated strong subvariant-specific responses among SOT recipients. Booster-induced cell-mediated immunity, however, remained lower than in immunocompetent individuals.

背景:奥密克戎BA.4/BA5-适应型二价加强疫苗在实体器官移植(SOT)后引发的免疫原性尚未得到表征。方法:我们评估了在基线和2 在30名接种了≥3剂单价疫苗的SOT受试者中,接种基于信使核糖核酸的二价(祖先菌株和BA.4/BA.5亚变体)疫苗后周。46.7%的患者有2019年冠状病毒病史。我们还招募了一个由19名非转基因健康个体组成的对照组。用荧光ELISA法测定干扰素(IFN)-γ分泌的细胞介导的免疫,而用竞争ELISA法测定针对BA.4/BA.5刺突受体结合域的中和IgG抗体反应 升压后周(83.8对133.0 SFU/106外周血单核细胞;P = 血清阳性率也有所上升(46.7%-83.3%;P = 0.001)以及血清中和活性(4.2%-78.3%;P 6个外周血单核细胞;P 结论:BA.4/BA5-适应二价疫苗的加强剂在SOT受试者中产生了强烈的亚变体特异性反应。然而,加强剂诱导的细胞介导的免疫仍然低于免疫活性个体。
{"title":"Cell-mediated and Neutralizing Antibody Responses to the SARS-CoV-2 Omicron BA.4/BA.5-adapted Bivalent Vaccine Booster in Kidney and Liver Transplant Recipients.","authors":"Mario Fernández-Ruiz, Patricia Almendro-Vázquez, Natalia Redondo, Tamara Ruiz-Merlo, Sandra Abella, Adán Somoza, Francisco López-Medrano, Rafael San Juan, Carmelo Loinaz, Amado Andrés, Estela Paz-Artal, José María Aguado","doi":"10.1097/TXD.0000000000001536","DOIUrl":"10.1097/TXD.0000000000001536","url":null,"abstract":"<p><strong>Background: </strong>The immunogenicity elicited by the Omicron BA.4/BA.5-adapted bivalent booster vaccine after solid organ transplantation (SOT) has not been characterized.</p><p><strong>Methods: </strong>We assessed cell-mediated and neutralizing IgG antibody responses against the BA.4/BA.5 spike receptor-binding domain at baseline and 2 wk after the administration of an mRNA-based bivalent (ancestral strain and BA.4/BA.5 subvariants) vaccine among 30 SOT recipients who had received ≥3 monovalent vaccine doses. Previous coronavirus disease 2019 history was present in 46.7% of them. We also recruited a control group of 19 nontransplant healthy individuals. Cell-mediated immunity was measured by fluorescent ELISpot assay for interferon (IFN)-γ secretion, whereas the neutralizing IgG antibody response against the BA.4/BA.5 spike receptor-binding domain was quantified with a competitive ELISA.</p><p><strong>Results: </strong>The median number of BA.4/BA.5 spike-specific IFN-γ-producing spot-forming units (SFUs) increased from baseline to 2 wk postbooster (83.8 versus 133.0 SFUs/10<sup>6</sup> peripheral blood mononuclear cells; <i>P</i> = 0.0017). Seropositivity rate also increased (46.7%-83.3%; <i>P</i> = 0.001), as well as serum neutralizing activity (4.2%-78.3%; <i>P</i> < 0.0001). Patients with no prior coronavirus disease 2019 history experienced higher improvements in cell-mediated and neutralizing responses after booster vaccination. There was no correlation between BA.4/BA.5 spike-specific IFN-γ-producing SFUs and neutralizing activity. Nontransplant controls showed more robust postbooster cell-mediated immunity than SOT recipients (591.1 versus 133.0 IFN-γ-producing SFUs/10<sup>6</sup> peripheral blood mononuclear cells; <i>P</i> < 0.0001), although no differences were observed for antibody responses in terms of postbooster seropositivity rates or neutralizing activity.</p><p><strong>Conclusions: </strong>Booster with the BA.4/BA.5-adapted bivalent vaccine generated strong subvariant-specific responses among SOT recipients. Booster-induced cell-mediated immunity, however, remained lower than in immunocompetent individuals.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"9 10","pages":"e1536"},"PeriodicalIF":1.9,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/09/txd-9-e1536.PMC10513127.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41172077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection of Bacterial Colonization in Lung Transplant Recipients Using an Electronic Nose. 用电子鼻检测肺移植受者的细菌定植。
IF 2.3 Q3 TRANSPLANTATION Pub Date : 2023-09-20 eCollection Date: 2023-10-01 DOI: 10.1097/TXD.0000000000001533
Nynke Wijbenga, Nadine L A de Jong, Rogier A S Hoek, Bas J Mathot, Leonard Seghers, Joachim G J V Aerts, Daniel Bos, Olivier C Manintveld, Merel E Hellemons

Background: Bacterial colonization (BC) of the lower airways is common in lung transplant recipients (LTRs) and increases the risk of chronic lung allograft dysfunction. Diagnosis often requires bronchoscopy. Exhaled breath analysis using electronic nose (eNose) technology may noninvasively detect BC in LTRs. Therefore, we aimed to assess the diagnostic accuracy of an eNose to detect BC in LTRs.

Methods: We performed a cross-sectional analysis within a prospective, single-center cohort study assessing the diagnostic accuracy of detecting BC using eNose technology in LTRs. In the outpatient clinic, consecutive LTR eNose measurements were collected. We assessed and classified the eNose measurements for the presence of BC. Using supervised machine learning, the diagnostic accuracy of eNose for BC was assessed in a random training and validation set. Model performance was evaluated using receiver operating characteristic analysis.

Results: In total, 161 LTRs were included with 80 exclusions because of various reasons. Of the remaining 81 patients, 16 (20%) were classified as BC and 65 (80%) as non-BC. eNose-based classification of patients with and without BC provided an area under the curve of 0.82 in the training set and 0.97 in the validation set.

Conclusions: Exhaled breath analysis using eNose technology has the potential to noninvasively detect BC.

背景:下呼吸道细菌定植(BC)在肺移植受者中很常见,并增加了慢性肺移植功能障碍的风险。诊断通常需要支气管镜检查。使用电子鼻(eNose)技术的呼气分析可以无创地检测LTR中的BC。因此,我们旨在评估eNose在LTR中检测BC的诊断准确性。方法:我们在一项前瞻性单中心队列研究中进行了横断面分析,评估使用eNose技术在LTR检测BC的准确性。在门诊部,收集连续的LTR eNose测量值。我们评估并分类了eNose测量的BC的存在。使用监督机器学习,在随机训练和验证集中评估eNose对BC的诊断准确性。使用接收器操作特性分析来评估模型性能。结果:由于各种原因,共有161份LTR被纳入,其中80份被排除在外。在剩下的81名患者中,16名(20%)被归类为BC,65名(80%)为非BC。对患有和不患有BC的患者进行基于eNose的分类,在训练集中提供了0.82的曲线下面积,在验证集中提供了0.97的曲线下区域。结论:使用eNose技术进行呼气分析具有无创检测BC的潜力。
{"title":"Detection of Bacterial Colonization in Lung Transplant Recipients Using an Electronic Nose.","authors":"Nynke Wijbenga,&nbsp;Nadine L A de Jong,&nbsp;Rogier A S Hoek,&nbsp;Bas J Mathot,&nbsp;Leonard Seghers,&nbsp;Joachim G J V Aerts,&nbsp;Daniel Bos,&nbsp;Olivier C Manintveld,&nbsp;Merel E Hellemons","doi":"10.1097/TXD.0000000000001533","DOIUrl":"https://doi.org/10.1097/TXD.0000000000001533","url":null,"abstract":"<p><strong>Background: </strong>Bacterial colonization (BC) of the lower airways is common in lung transplant recipients (LTRs) and increases the risk of chronic lung allograft dysfunction. Diagnosis often requires bronchoscopy. Exhaled breath analysis using electronic nose (eNose) technology may noninvasively detect BC in LTRs. Therefore, we aimed to assess the diagnostic accuracy of an eNose to detect BC in LTRs.</p><p><strong>Methods: </strong>We performed a cross-sectional analysis within a prospective, single-center cohort study assessing the diagnostic accuracy of detecting BC using eNose technology in LTRs. In the outpatient clinic, consecutive LTR eNose measurements were collected. We assessed and classified the eNose measurements for the presence of BC. Using supervised machine learning, the diagnostic accuracy of eNose for BC was assessed in a random training and validation set. Model performance was evaluated using receiver operating characteristic analysis.</p><p><strong>Results: </strong>In total, 161 LTRs were included with 80 exclusions because of various reasons. Of the remaining 81 patients, 16 (20%) were classified as BC and 65 (80%) as non-BC. eNose-based classification of patients with and without BC provided an area under the curve of 0.82 in the training set and 0.97 in the validation set.</p><p><strong>Conclusions: </strong>Exhaled breath analysis using eNose technology has the potential to noninvasively detect BC.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"9 10","pages":"e1533"},"PeriodicalIF":2.3,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/37/txd-9-e1533.PMC10513211.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41172135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex and Gender Disparities in Living Kidney Donation: A Scoping Review. 活体肾脏捐献中的性别差异:范围综述。
IF 2.3 Q3 TRANSPLANTATION Pub Date : 2023-09-01 DOI: 10.1097/TXD.0000000000001530
Eswari Vilayur, Anita van Zwieten, Mingxing Chen, Anna Francis, Melanie Wyld, Siah Kim, Tess Cooper, Germaine Wong

Background: Women are more likely than men to be living kidney donors. We summarized the evidence concerning the reasons behind sex and gender disparities in living kidney donation (LKD).

Methods: A scoping review of quantitative and qualitative evidence on reasons for sex and gender disparities in LKD was conducted from inception to March 2023.

Results: Of 1123 studies screened, 45 were eligible for inclusion. Most studies were from North America, Europe, and Central Asia (n = 33, 73%). A predominance of women as living donors (55%-65%) was observed in 15 out of 18 (83%) studies. Reasons for sex and gender disparities in LKD included socioeconomic, biological, and cognitive or emotional factors. A gendered division of roles within the families was observed in most studies, with men being the primary income earner and women being the main caregiver. Fear of loss of income was a barrier to male donation. Human leukocyte antigen sensitization through pregnancy in female recipients precluded male partner donation, whereas female donation was supported by altruism and a positive attitude toward LKD.

Conclusions: Sex imbalance in LKD is prevalent, with a predominance of women as living donors. Such disparities are driven by societal and cultural perceptions of gender roles, pregnancy-induced sensitization, and attitudes toward donation and at least some of these factors are modifiable. Donor compensation to support predonation assessments and income loss, implementation of innovative desensitization treatments, promotion of paired kidney exchange program, and targeted educational initiatives to promote equitable living donation may help to close the gender gap in LKD.

背景:女性比男性更有可能成为活体肾脏捐赠者。我们总结了活肾捐献(LKD)中性别差异背后的原因。方法:从成立到2023年3月,对LKD的性别和性别差异的原因进行了定量和定性证据的范围审查。结果:在筛选的1123项研究中,有45项符合纳入条件。大多数研究来自北美、欧洲和中亚(n = 33, 73%)。在18项(83%)研究中有15项观察到妇女作为活体献血者占多数(55%-65%)。LKD中性别差异的原因包括社会经济、生物学和认知或情感因素。在大多数研究中观察到家庭中的性别角色分工,男子是主要的收入来源,妇女是主要的照顾者。担心失去收入是男性捐赠的一个障碍。女性受体在怀孕过程中产生的人类白细胞抗原致敏性阻止了男性伴侣的捐献,而女性的捐献则受到利他主义和对LKD的积极态度的支持。结论:LKD的性别失衡是普遍存在的,以女性作为活体献血者居多。这种差异是由社会和文化对性别角色的看法、妊娠致敏和对捐赠的态度造成的,至少其中一些因素是可以改变的。捐赠补偿以支持捐赠前评估和收入损失,实施创新脱敏治疗,促进配对肾脏交换计划,以及有针对性的教育举措以促进公平的生活捐赠,可能有助于缩小LKD中的性别差距。
{"title":"Sex and Gender Disparities in Living Kidney Donation: A Scoping Review.","authors":"Eswari Vilayur,&nbsp;Anita van Zwieten,&nbsp;Mingxing Chen,&nbsp;Anna Francis,&nbsp;Melanie Wyld,&nbsp;Siah Kim,&nbsp;Tess Cooper,&nbsp;Germaine Wong","doi":"10.1097/TXD.0000000000001530","DOIUrl":"https://doi.org/10.1097/TXD.0000000000001530","url":null,"abstract":"<p><strong>Background: </strong>Women are more likely than men to be living kidney donors. We summarized the evidence concerning the reasons behind sex and gender disparities in living kidney donation (LKD).</p><p><strong>Methods: </strong>A scoping review of quantitative and qualitative evidence on reasons for sex and gender disparities in LKD was conducted from inception to March 2023.</p><p><strong>Results: </strong>Of 1123 studies screened, 45 were eligible for inclusion. Most studies were from North America, Europe, and Central Asia (n = 33, 73%). A predominance of women as living donors (55%-65%) was observed in 15 out of 18 (83%) studies. Reasons for sex and gender disparities in LKD included socioeconomic, biological, and cognitive or emotional factors. A gendered division of roles within the families was observed in most studies, with men being the primary income earner and women being the main caregiver. Fear of loss of income was a barrier to male donation. Human leukocyte antigen sensitization through pregnancy in female recipients precluded male partner donation, whereas female donation was supported by altruism and a positive attitude toward LKD.</p><p><strong>Conclusions: </strong>Sex imbalance in LKD is prevalent, with a predominance of women as living donors. Such disparities are driven by societal and cultural perceptions of gender roles, pregnancy-induced sensitization, and attitudes toward donation and at least some of these factors are modifiable. Donor compensation to support predonation assessments and income loss, implementation of innovative desensitization treatments, promotion of paired kidney exchange program, and targeted educational initiatives to promote equitable living donation may help to close the gender gap in LKD.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"9 9","pages":"e1530"},"PeriodicalIF":2.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/e2/txd-9-e1530.PMC10455160.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10482371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Donor-derived Epstein-Barr Virus Mucocutaneous Ulceration: A Unique and Complex Case of Rectal Hemorrhage. 供体来源的eb病毒粘膜皮肤溃疡:一个独特而复杂的直肠出血病例。
IF 2.3 Q3 TRANSPLANTATION Pub Date : 2023-09-01 DOI: 10.1097/TXD.0000000000001510
John Fallon, Anito Rendek, Paul Harden, Venkatesha Udupa
E pstein-Barr virus (EBV) is pervasive, with a significant proportion of humans being asymptomatic carriers. Latent infection risk is an issue in the immunosuppressed because of the exerted effects of expressed viral proteins on B-lymphocyte maturation and proliferation or because of T-lymphocyte reaction. 1,2 This interaction produces a spectrum of lymphoproliferative disorders that includes EBV-mucocutaneous ulcer (MCU), in which the most severe disease process on the spectrum is posttransplant lymphoproliferative disorder (PTLD). 3 EBV-MCU is separate from PTLD, because of its indolent clinical course, without its progression to disseminated disease, and despite a significant degree of cytological atypia seen histologically. 4 Although it may not disseminate, it can be locally destructive and, in the case we discuss here, is the only EBV-MCU in the literature in the rectal mucosa to pre-sent with rectal hemorrhage. Hemorrhage in a young post-transplant patient is difficult to manage, given reluctance for multiple sensitizing blood transfusions, especially if, as in this case, they are reliant on anticoagulation.
{"title":"Donor-derived Epstein-Barr Virus Mucocutaneous Ulceration: A Unique and Complex Case of Rectal Hemorrhage.","authors":"John Fallon,&nbsp;Anito Rendek,&nbsp;Paul Harden,&nbsp;Venkatesha Udupa","doi":"10.1097/TXD.0000000000001510","DOIUrl":"https://doi.org/10.1097/TXD.0000000000001510","url":null,"abstract":"E pstein-Barr virus (EBV) is pervasive, with a significant proportion of humans being asymptomatic carriers. Latent infection risk is an issue in the immunosuppressed because of the exerted effects of expressed viral proteins on B-lymphocyte maturation and proliferation or because of T-lymphocyte reaction. 1,2 This interaction produces a spectrum of lymphoproliferative disorders that includes EBV-mucocutaneous ulcer (MCU), in which the most severe disease process on the spectrum is posttransplant lymphoproliferative disorder (PTLD). 3 EBV-MCU is separate from PTLD, because of its indolent clinical course, without its progression to disseminated disease, and despite a significant degree of cytological atypia seen histologically. 4 Although it may not disseminate, it can be locally destructive and, in the case we discuss here, is the only EBV-MCU in the literature in the rectal mucosa to pre-sent with rectal hemorrhage. Hemorrhage in a young post-transplant patient is difficult to manage, given reluctance for multiple sensitizing blood transfusions, especially if, as in this case, they are reliant on anticoagulation.","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"9 9","pages":"e1510"},"PeriodicalIF":2.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bb/1f/txd-9-e1510.PMC10414712.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9998228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The First Collective Examination of Immunosuppressive Practices Among American Intestinal Transplant Centers. 美国肠道移植中心免疫抑制实践的首次集体检查。
IF 2.3 Q3 TRANSPLANTATION Pub Date : 2023-09-01 DOI: 10.1097/TXD.0000000000001512
Joshua Weiner, Nathaly Llore, Dylan Ormsby, Masato Fujiki, Maria Cristina Segovia, Mark Obri, Syed-Mohammed Jafri, Jedson Liggett, Alexander H K Kroemer, Cal Matsumoto, Jang Moon, Pierpaolo Di Cocco, Gennaro Selvaggi, Jennifer Garcia, Armando Ganoza, Ajai Khanna, George Mazariegos, Danielle Wendel, Jorge Reyes

Background: Unlike other solid organs, no standardized treatment algorithms exist for intestinal transplantation (ITx). We established a consortium of American ITx centers to evaluate current practices.

Methods: All American centers performing ITx during the past 3 y were invited to participate. As a consortium, we generated questions to evaluate and collect data from each institution. The data were compiled and analyzed.

Results: Ten centers participated, performing 211 ITx during the past 3 y (range, 3-46; mean 21.1). Induction regimens varied widely. Thymoglobulin was the most common, used in the plurality of patients (85/211; 40.3%), but there was no consensus regimen. Similarly, regimens for the treatment of acute cellular rejection, antibody-mediated rejection, and graft-versus-host disease varied significantly between centers. We also evaluated differences in maintenance immunosuppression protocols, desensitization regimens, mammalian target of rapamycin use, antimetabolite use, and posttransplantation surveillance practices. Maintenance tacrolimus levels, stoma presence, and scoping frequency were not associated with differences in rejection events. Definitive association between treatments and outcomes, including graft and patient survival, was not the intention of this initial collaboration and is prevented by the lack of patient-level data and the presence of confounders. However, we identified trends regarding rejection episodes after various induction strategies that require further investigation in our subsequent collaborations.

Conclusions: This initial collaboration reveals the extreme heterogeneity of practices among American ITx centers. Future collaboration will explore patient-level data, stratified by age and transplant type (isolated intestine versus multivisceral), to explore the association between treatment regimens and outcomes.

背景:与其他实体器官不同,肠移植(ITx)没有标准化的治疗算法。我们建立了一个由美国ITx中心组成的联盟来评估当前的实践。方法:邀请所有在过去3年内进行ITx的美国中心参与。作为一个联合体,我们产生了一些问题来评估和收集来自每个机构的数据。对数据进行了汇编和分析。结果:10个中心参与,在过去的3年中进行了211次ITx(范围,3-46;意思是21.1)。诱导方案差别很大。胸腺球蛋白是最常见的,在多数患者中使用(85/211;40.3%),但没有共识方案。同样,治疗急性细胞排斥反应、抗体介导的排斥反应和移植物抗宿主病的方案在各中心之间也有显著差异。我们还评估了维持免疫抑制方案、脱敏方案、哺乳动物雷帕霉素靶点使用、抗代谢物使用和移植后监测实践的差异。维持他克莫司水平、造口存在和范围检查频率与排斥事件的差异无关。治疗和结果(包括移植物和患者生存)之间的明确关联并不是最初合作的目的,并且由于缺乏患者水平的数据和混杂因素的存在而受到阻碍。然而,我们确定了各种诱导策略后排斥事件的趋势,需要在我们随后的合作中进一步研究。结论:这一初步合作揭示了美国ITx中心实践的极端异质性。未来的合作将探索患者水平的数据,按年龄和移植类型(分离肠与多内脏)分层,以探索治疗方案和结果之间的关系。
{"title":"The First Collective Examination of Immunosuppressive Practices Among American Intestinal Transplant Centers.","authors":"Joshua Weiner,&nbsp;Nathaly Llore,&nbsp;Dylan Ormsby,&nbsp;Masato Fujiki,&nbsp;Maria Cristina Segovia,&nbsp;Mark Obri,&nbsp;Syed-Mohammed Jafri,&nbsp;Jedson Liggett,&nbsp;Alexander H K Kroemer,&nbsp;Cal Matsumoto,&nbsp;Jang Moon,&nbsp;Pierpaolo Di Cocco,&nbsp;Gennaro Selvaggi,&nbsp;Jennifer Garcia,&nbsp;Armando Ganoza,&nbsp;Ajai Khanna,&nbsp;George Mazariegos,&nbsp;Danielle Wendel,&nbsp;Jorge Reyes","doi":"10.1097/TXD.0000000000001512","DOIUrl":"https://doi.org/10.1097/TXD.0000000000001512","url":null,"abstract":"<p><strong>Background: </strong>Unlike other solid organs, no standardized treatment algorithms exist for intestinal transplantation (ITx). We established a consortium of American ITx centers to evaluate current practices.</p><p><strong>Methods: </strong>All American centers performing ITx during the past 3 y were invited to participate. As a consortium, we generated questions to evaluate and collect data from each institution. The data were compiled and analyzed.</p><p><strong>Results: </strong>Ten centers participated, performing 211 ITx during the past 3 y (range, 3-46; mean 21.1). Induction regimens varied widely. Thymoglobulin was the most common, used in the plurality of patients (85/211; 40.3%), but there was no consensus regimen. Similarly, regimens for the treatment of acute cellular rejection, antibody-mediated rejection, and graft-versus-host disease varied significantly between centers. We also evaluated differences in maintenance immunosuppression protocols, desensitization regimens, mammalian target of rapamycin use, antimetabolite use, and posttransplantation surveillance practices. Maintenance tacrolimus levels, stoma presence, and scoping frequency were not associated with differences in rejection events. Definitive association between treatments and outcomes, including graft and patient survival, was not the intention of this initial collaboration and is prevented by the lack of patient-level data and the presence of confounders. However, we identified trends regarding rejection episodes after various induction strategies that require further investigation in our subsequent collaborations.</p><p><strong>Conclusions: </strong>This initial collaboration reveals the extreme heterogeneity of practices among American ITx centers. Future collaboration will explore patient-level data, stratified by age and transplant type (isolated intestine versus multivisceral), to explore the association between treatment regimens and outcomes.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"9 9","pages":"e1512"},"PeriodicalIF":2.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/03/ca/txd-9-e1512.PMC10455426.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10160439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tuberculosis in Kidney Transplant Recipients: A Nationwide Cohort in a Low Tuberculosis Incidence Country. 肾移植受者的结核:一个低结核发病率国家的全国性队列。
IF 2.3 Q3 TRANSPLANTATION Pub Date : 2023-09-01 DOI: 10.1097/TXD.0000000000001527
Thijs Feuth, Iiris Rajalahti, Tuula Vasankari, Mika Gissler, Ruska Rimhanen-Finne, Patrik Finne, Ilkka Helanterä

Background: World Health Organization recommends tuberculosis (TB) preventive treatment for risk groups such as patients preparing for organ transplantation. Pretransplant screening or treatment of latent TB infection has not been routine practice in Finland.

Methods: In this nationwide registry study, we assessed the risk of TB among kidney transplant recipients compared to the general population. TB cases were identified by data linkage of the national infectious disease and the national transplant registries between 1995 and 2019. Standardized incidence ratios were calculated with adjustment for age, sex, and annual TB dynamics.

Results: A total of 4101 kidney transplants in 3900 recipients with a follow-up of 37 652 patient-years were included. Eighteen TB cases were detected. Patients diagnosed with TB were older (median age 64 y, interquartile range 56-66) at transplantation than those without TB (median 51 y, interquartile range 41-60, P < 0.001). The standardized incidence ratio of TB was 6.9 among kidney transplant recipients compared to general population during the whole study period 1995-2019 but decreased from 12.5 in 1995-2007 to 3.2 in 2008-2019. The standardized incidence ratio was 44.2 during the first year after transplantation. Significant differences in 5-y graft losses were not detected between TB patients and those without TB.

Conclusions: The standardized incidence ratio of TB in kidney transplant recipients has decreased over the years, but these patients remain at risk of TB, especially during the first posttransplant year. Cost-benefit analysis is required to address feasibility of latent TB infection screening among transplant candidates in countries with low incidence of TB.

背景:世界卫生组织建议对高危人群(如准备器官移植的患者)进行结核病预防治疗。在芬兰,移植前筛查或治疗潜伏性结核感染尚未成为常规做法。方法:在这项全国性的登记研究中,我们评估了肾移植受者与普通人群相比发生结核病的风险。通过1995年至2019年期间国家传染病和国家移植登记处的数据链接确定了结核病病例。通过调整年龄、性别和年度结核病动态来计算标准化发病率。结果:共纳入3900例受者的4101例肾移植,随访37652例患者年。发现了18例结核病例。诊断为结核病的患者在移植时年龄较大(中位年龄64岁,四分位数范围56-66),而非结核病患者(中位年龄51岁,四分位数范围41-60,P < 0.001)。在1995-2019年的整个研究期间,与普通人群相比,肾移植受者的结核病标准化发病率为6.9,但从1995-2007年的12.5降至2008-2019年的3.2。移植后第一年标准化发生率为44.2。在结核患者和非结核患者之间未发现5-y移植物损失的显著差异。结论:近年来,肾移植受者结核病的标准化发病率有所下降,但这些患者仍然存在结核病的风险,特别是在移植后的第一年。需要进行成本效益分析,以解决在结核病发病率低的国家对移植候选者进行潜伏结核感染筛查的可行性。
{"title":"Tuberculosis in Kidney Transplant Recipients: A Nationwide Cohort in a Low Tuberculosis Incidence Country.","authors":"Thijs Feuth,&nbsp;Iiris Rajalahti,&nbsp;Tuula Vasankari,&nbsp;Mika Gissler,&nbsp;Ruska Rimhanen-Finne,&nbsp;Patrik Finne,&nbsp;Ilkka Helanterä","doi":"10.1097/TXD.0000000000001527","DOIUrl":"https://doi.org/10.1097/TXD.0000000000001527","url":null,"abstract":"<p><strong>Background: </strong>World Health Organization recommends tuberculosis (TB) preventive treatment for risk groups such as patients preparing for organ transplantation. Pretransplant screening or treatment of latent TB infection has not been routine practice in Finland.</p><p><strong>Methods: </strong>In this nationwide registry study, we assessed the risk of TB among kidney transplant recipients compared to the general population. TB cases were identified by data linkage of the national infectious disease and the national transplant registries between 1995 and 2019. Standardized incidence ratios were calculated with adjustment for age, sex, and annual TB dynamics.</p><p><strong>Results: </strong>A total of 4101 kidney transplants in 3900 recipients with a follow-up of 37 652 patient-years were included. Eighteen TB cases were detected. Patients diagnosed with TB were older (median age 64 y, interquartile range 56-66) at transplantation than those without TB (median 51 y, interquartile range 41-60, <i>P</i> < 0.001). The standardized incidence ratio of TB was 6.9 among kidney transplant recipients compared to general population during the whole study period 1995-2019 but decreased from 12.5 in 1995-2007 to 3.2 in 2008-2019. The standardized incidence ratio was 44.2 during the first year after transplantation. Significant differences in 5-y graft losses were not detected between TB patients and those without TB.</p><p><strong>Conclusions: </strong>The standardized incidence ratio of TB in kidney transplant recipients has decreased over the years, but these patients remain at risk of TB, especially during the first posttransplant year. Cost-benefit analysis is required to address feasibility of latent TB infection screening among transplant candidates in countries with low incidence of TB.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"9 9","pages":"e1527"},"PeriodicalIF":2.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/1b/txd-9-e1527.PMC10455224.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10482375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of Individual Components of Frailty in Simultaneous Pancreas and Kidney, and Solitary Pancreas Transplant Recipients. 胰腺和肾脏同时移植及单独胰腺移植受者衰弱的个体成分分析。
IF 2.3 Q3 TRANSPLANTATION Pub Date : 2023-09-01 DOI: 10.1097/TXD.0000000000001523
Sandesh Parajuli, Jon Odorico, Isabel Breyer, Emily Zona, Fahad Aziz, Heather Lorden, Jacqueline Garonzik-Wang, Dixon Kaufman, Didier Mandelbrot

Backgrounds: It is not known which of the 5 components of the Fried frailty score have the most predictive value for outcomes in simultaneous pancreas-kidney transplant (SPK) and solitary pancreas transplant (SPT) recipients.

Methods: In this study, we sought to investigate the association between pretransplant overall frailty and individual frailty components, with posttransplant outcomes among SPK and SPT recipients. Outcomes of interest were length of stay, kidney delayed graft function (K-DGF), readmission within 30 d after discharge, cardiovascular events, acute rejection, pancreas death-censored graft failure (DCGF), kidney DCGF, and death.

Results: Of the individual frailty components among SPK (n = 113), only slow walk time was associated with an increased risk of mortality (adjusted odds ratio [aOR]: 4.99; P = 0.03). Among SPT (n = 49), higher sum frailty scores (coefficient correlation 0.29; P = 0.04) and weight loss (coefficient correlation  = 0.30; P = 0.03) were associated with prolonged length of stay. Similarly, weight loss among SPT was associated with an increased risk of DCGF (aOR: 4.34; P = 0.049). Low grip strength was strongly associated with an increased risk of early readmission (aOR: 13.08; P = 0.008).

Conclusions: We found that not all components of frailty contribute equally to predicting outcomes. Objective measurements of slow walk time, unintentional weight loss, and low grip strength were found to be associated with less optimal outcomes in pancreas transplant recipients. Targeted interventions may improve posttransplant outcomes.

背景:目前尚不清楚Fried衰弱评分的5个组成部分中哪一个对同时胰肾移植(SPK)和单独胰移植(SPT)受者的预后最有预测价值。方法:在本研究中,我们试图调查SPK和SPT受者移植前整体虚弱和个体虚弱成分与移植后预后之间的关系。关注的结果是住院时间、肾延迟移植功能(K-DGF)、出院后30天内再入院、心血管事件、急性排斥反应、胰腺死亡审查移植失败(DCGF)、肾脏DCGF和死亡。结果:在SPK个体虚弱因素(n = 113)中,只有缓慢步行时间与死亡风险增加相关(调整优势比[aOR]: 4.99;P = 0.03)。在SPT组(n = 49)中,虚弱总分较高(相关系数0.29;P = 0.04)和体重减轻(相关系数= 0.30;P = 0.03)与住院时间延长有关。同样,SPT患者体重减轻与DCGF风险增加相关(aOR: 4.34;P = 0.049)。握力低与早期再入院风险增加密切相关(aOR: 13.08;P = 0.008)。结论:我们发现并非虚弱的所有组成部分对预测结果的贡献相同。在胰腺移植受者中,缓慢的步行时间、无意的体重减轻和低握力的客观测量被发现与较不理想的结果相关。有针对性的干预可能改善移植后的预后。
{"title":"Analysis of Individual Components of Frailty in Simultaneous Pancreas and Kidney, and Solitary Pancreas Transplant Recipients.","authors":"Sandesh Parajuli,&nbsp;Jon Odorico,&nbsp;Isabel Breyer,&nbsp;Emily Zona,&nbsp;Fahad Aziz,&nbsp;Heather Lorden,&nbsp;Jacqueline Garonzik-Wang,&nbsp;Dixon Kaufman,&nbsp;Didier Mandelbrot","doi":"10.1097/TXD.0000000000001523","DOIUrl":"https://doi.org/10.1097/TXD.0000000000001523","url":null,"abstract":"<p><strong>Backgrounds: </strong>It is not known which of the 5 components of the Fried frailty score have the most predictive value for outcomes in simultaneous pancreas-kidney transplant (SPK) and solitary pancreas transplant (SPT) recipients.</p><p><strong>Methods: </strong>In this study, we sought to investigate the association between pretransplant overall frailty and individual frailty components, with posttransplant outcomes among SPK and SPT recipients. Outcomes of interest were length of stay, kidney delayed graft function (K-DGF), readmission within 30 d after discharge, cardiovascular events, acute rejection, pancreas death-censored graft failure (DCGF), kidney DCGF, and death.</p><p><strong>Results: </strong>Of the individual frailty components among SPK (n = 113), only slow walk time was associated with an increased risk of mortality (adjusted odds ratio [aOR]: 4.99; <i>P</i> = 0.03). Among SPT (n = 49), higher sum frailty scores (coefficient correlation 0.29; <i>P</i> = 0.04) and weight loss (coefficient correlation  = 0.30; <i>P</i> = 0.03) were associated with prolonged length of stay. Similarly, weight loss among SPT was associated with an increased risk of DCGF (aOR: 4.34; <i>P</i> = 0.049). Low grip strength was strongly associated with an increased risk of early readmission (aOR: 13.08; <i>P</i> = 0.008).</p><p><strong>Conclusions: </strong>We found that not all components of frailty contribute equally to predicting outcomes. Objective measurements of slow walk time, unintentional weight loss, and low grip strength were found to be associated with less optimal outcomes in pancreas transplant recipients. Targeted interventions may improve posttransplant outcomes.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"9 9","pages":"e1523"},"PeriodicalIF":2.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/b9/txd-9-e1523.PMC10465099.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10500931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transplant Center Attitudes Toward Early Liver Transplant for Alcohol-associated Liver Disease. 移植中心对酒精相关性肝病早期肝移植的态度
IF 2.3 Q3 TRANSPLANTATION Pub Date : 2023-09-01 DOI: 10.1097/TXD.0000000000001532
Jonathan Mitchell, Kayleigh Herrick-Reynolds, Jennifer D Motter, Mayan Teles, Olivia Kates, Hannah Sung, Po-Hung Chen, Elizabeth King, Andrew Cameron

Background: Many centers have removed 6-mo pretransplant alcohol abstinence requirements to provide early liver transplant (ELT) for individuals with severe alcohol-associated liver disease (ALD), but the practice remains controversial. Using data collected from a nationally distributed survey, this study examines the practices and attitudes of transplant centers in the United States regarding ELT.

Methods: A 20-item survey designed to assess center practices and provider attitudes was distributed to 225 medical and surgical directors from 143 liver transplant centers via email.

Results: Surveys were completed by 28.9% (n = 65) of directors and 39% (n = 56) of transplant centers. All responding centers reported evaluating patients for ELT. Circumstances for considering ELT included <6 mo of survival without a transplant (96.4%) and inability to participate in alcohol addiction therapy pretransplant (75%). Most (66%) directors indicated their center had established criteria for listing candidates with severe ALD for ELT. Regarding important factors for ELT candidate listing, 57.1% indicated patient survival, 37.5% indicated graft survival, and 55.4% indicated having a low risk of relapse. Only 12.7% of directors affirmed the statement, "Six months of pretransplant abstinence decreases the risk of relapse."

Conclusions: More centers are providing ELT for severe ALD. Inability to participate in alcohol addiction therapy and <6 mo of survival are commonly reported circumstances for considering ELT. Continued investigation of posttransplant outcomes in patients receiving ELT is essential to establishing a national consensus for distributing this valuable resource.

背景:许多中心已经取消了移植前6个月的戒酒要求,以便为患有严重酒精相关性肝病(ALD)的患者提供早期肝移植(ELT),但这种做法仍然存在争议。使用从全国分布的调查中收集的数据,本研究考察了美国移植中心关于ELT的做法和态度。方法:通过电子邮件向143家肝移植中心的225名内科和外科主任发送一份20个项目的调查问卷,以评估中心的做法和提供者的态度。结果:28.9%的主任(n = 65)和39%的移植中心(n = 56)完成了调查。所有应答中心均报告对患者进行ELT评估。结论:越来越多的中心为重度ALD患者提供ELT治疗。无法参加酒精成瘾治疗
{"title":"Transplant Center Attitudes Toward Early Liver Transplant for Alcohol-associated Liver Disease.","authors":"Jonathan Mitchell,&nbsp;Kayleigh Herrick-Reynolds,&nbsp;Jennifer D Motter,&nbsp;Mayan Teles,&nbsp;Olivia Kates,&nbsp;Hannah Sung,&nbsp;Po-Hung Chen,&nbsp;Elizabeth King,&nbsp;Andrew Cameron","doi":"10.1097/TXD.0000000000001532","DOIUrl":"https://doi.org/10.1097/TXD.0000000000001532","url":null,"abstract":"<p><strong>Background: </strong>Many centers have removed 6-mo pretransplant alcohol abstinence requirements to provide early liver transplant (ELT) for individuals with severe alcohol-associated liver disease (ALD), but the practice remains controversial. Using data collected from a nationally distributed survey, this study examines the practices and attitudes of transplant centers in the United States regarding ELT.</p><p><strong>Methods: </strong>A 20-item survey designed to assess center practices and provider attitudes was distributed to 225 medical and surgical directors from 143 liver transplant centers via email.</p><p><strong>Results: </strong>Surveys were completed by 28.9% (n = 65) of directors and 39% (n = 56) of transplant centers. All responding centers reported evaluating patients for ELT. Circumstances for considering ELT included <6 mo of survival without a transplant (96.4%) and inability to participate in alcohol addiction therapy pretransplant (75%). Most (66%) directors indicated their center had established criteria for listing candidates with severe ALD for ELT. Regarding important factors for ELT candidate listing, 57.1% indicated patient survival, 37.5% indicated graft survival, and 55.4% indicated having a low risk of relapse. Only 12.7% of directors affirmed the statement, \"Six months of pretransplant abstinence decreases the risk of relapse.\"</p><p><strong>Conclusions: </strong>More centers are providing ELT for severe ALD. Inability to participate in alcohol addiction therapy and <6 mo of survival are commonly reported circumstances for considering ELT. Continued investigation of posttransplant outcomes in patients receiving ELT is essential to establishing a national consensus for distributing this valuable resource.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"9 9","pages":"e1532"},"PeriodicalIF":2.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10157693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Transplantation Direct
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1